Exhibit 16.1
4 April 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated April 4, 2022, of Royalty Pharma plc (the ‘‘Company’’) and are in agreement with the statements contained in the section (a) on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young
Dublin, Ireland